Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib

Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events

(2018) Rhian M. Touyz et al.   Journal of the American Society of Hypertension

Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients

(2018) Matthias Totzeck et al.   European Journal of Preventive Cardiology

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

Cutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib

(2016) Veronica J. Shi et al.   JAMA Dermatology

Sorafenib Cardiotoxicity Increases Mortality After Myocardial Infarction

(2014) Jason M. Duran et al.   CIRCULATION RESEARCH

Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism

(2013) Toyonori Tsuzuki et al.   HISTOPATHOLOGY

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients

(2013) Philip S. Hall et al.   JACC-Heart Failure

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

(2012) Richard M. Steingart et al.   AMERICAN HEART JOURNAL

Reversible Cardiomyopathy Associated with Sunitinib and Sorafenib

(2011) Imran Uraizee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiotoxicity induced by tyrosine kinase inhibitors

(2009) George S. Orphanos et al.   ACTA ONCOLOGICA

Sorafenib-induced acute myocardial infarction due to coronary artery spasm

(2009) Yuichiro Arima et al.   Journal of Cardiology

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY